First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

被引：65

作者：

Siefker-Radtke, Arlene O.

Necchi, Andrea

Park, Se Hoon

GarcAa-Donas, JesAs

Huddart, Robert A.

Burgess, Earle Frederick

Fleming, Mark T.

Rezazadeh, Arash

Mellado, Begona

Varlamov, Sergei

Joshi, Monika

Duran, Ignacio

Tagawa, Scott T.

OHagan, Anne

Avadhani, Anjali Narayan

Zhong, Bob

De Porre, Peter

Loriot, Yohann

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Ist Nazl Tumori, Milan, Italy

[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[4] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain

[5] Inst Canc Res, Sutton, Surrey, England

[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[7] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA

[8] Norton Healthcare, Louisville, KY USA

[9] Inst Investigac Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain

[10] Altai Reg Canc Ctr, Barnaul, Russia

[11] Penn State Canc Inst, Hershey, PA USA

[12] Hosp Univ Marques Valdecilla, Santander, Spain

[13] Weill Cornell Med Coll, Div Hematol Med Oncol, Dept Urol, Meyer Canc Ctr, New York, NY USA

[14] New York Presbyterian Hosp, New York, NY USA

[15] Janssen Res & Dev, Spring House, PA USA

[16] Janssen Res & Dev, Beerse, Belgium

[17] Inst Gustave Roussy, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4503

引用

页数：2

共 50 条

[41] Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 for metastatic or surgically unresectable urothelial carcinoma harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) alterations
Shore, Neal D.
Asatiani, Ekaterine
Lihou, Christine F.
Zhen, Huiling
Gupta, Sumati
CANCER RESEARCH, 2017, 77
[42] Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).
Mellado, Begona
Castellano, Daniel E.
Pang, S.
Urun, Yuksul
Park, Se Hoon
Vaishampayan, Ulka N.
Pal, Sumanta K.
Currie, Graeme
Abella, Esteban
Vogl, Florian D.
Necchi, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
Barthelemy, P.
Thibault, C.
Voog, E.
Eymard, J-C.
Ravaud, A.
Flechon, A.
Jaillon, C. Abraham
Hilgers, W.
Le Moulec, S.
Chasseray, M.
Pouessel, D.
Amela, Y. E.
Lorgis, V.
Nicolas, E.
Kazan, E.
Denechere, G.
Solbes, M-N.
Lambert, P.
Loriot, Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1341 - S1342
[44] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
Bilen, M. A.
Xi, A. D.
Wong, A.
Schroeder, A.
Kim, R.
Liu, F. X.
Peng, J.
Robinson, S.
Bhanegaonkar, A.
ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
[45] KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.
Bajorin, Dean F.
Plimack, Elizabeth R.
Siefker-Radtke, Arlene O.
Choueiri, Toni K.
De Wit, Ronald
Sonpavde, Guru
Gipson, Adrianna
Brown, Holly
Mai, Yabing
Pang, Lei
Perini, Rodolfo F.
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[46] Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
Apolo, Andrea B.
Ellerton, John Allan
Infante, Jeffrey R.
Agrawal, Manish
Gordon, Michael S.
Aljumaily, Raid
Britten, Carolyn D.
Dirix, Luc Yves
Lee, Keun-Wook
Taylor, Matthew H.
Schoffski, Patrick
Wang, Ding
Ravaud, Alain
Gelb, Arnold
Xiong, Junyuan
Rosen, Galit
Patel, Manish R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[47] Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
Petrylak, Daniel P.
Tagawa, Scott T.
Jain, Rohit K.
Bupathi, Manojkumar
Balar, Arjun V.
Rezazadeh, Arash
George, Saby
Palmbos, Phillip Lee
Nordquist, Luke T.
Davis, Nancy B.
Ramamurthy, Chethan
Sternberg, Cora N.
Loriot, Yohann
Agarwal, Neeraj
Park, Chandler H.
Tonelli, Julia
Vance, Morganna
Zhou, Huafeng
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[48] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
Garmezy, Benjamin
Perez, Cesar Augusto
Kato, Shumei
Sharma, Manish
Quah, Cheng Seok
Tam, Betty
Severson, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[49] Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
Zemankova, Anezka
Studentova, Hana
Melichar, Bohuslav
Eid, Michal
Poprach, Alexandr
Kopecky, Jindrich
Spacek, Jan
Stuhlova, Sarka
Dvorak, Jan
Vlcek, Pavel
Zychackova, Katerina
Katolicka, Jana
Blazek, Tomas
Vrana, David
Majkova, Petra
Cepa, Adam
Fiala, Ondrej
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 557 - 557
[50] Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.
Grivas, Petros
Pouessel, Damien
Park, Chandler H.
Barthelemy, Philippe
Bupathi, Manojkumar
Petrylak, Daniel P.
Agarwal, Neeraj
Gupta, Sumati
Flechon, Aude
Ramamurthy, Chethan
Davis, Nancy B.
Recio-Boiles, Alejandro
Sternberg, Cora N.
Bhatia, Astha
Pichardo, Cabilia
Sierecki, Mitch
Tonelli, Julia
Zhou, Huafeng
Tagawa, Scott T.
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41

← 1 2 3 4 5 →